Evidence of progressive multifocal leukoencephalopathy (PML) identified on the pretreatment magnetic resonance imaging (MRI)
Absence of brain metastasis, as confirmed by a negative CT with contrast or magnetic resonance imaging (MRI) scan of the brain, no more than 4 weeks prior to randomization. Applicable only to metastasectomy participants
Part C: Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)
Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound; magnetic resonance imaging (MRI) or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy
Baseline imaging:
Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within 28 days prior to registration, which demonstrates measurable disease, as defined in RECIST v. 1.1; all disease must be assessed and documented on the S1609 Baseline Tumor Assessment Form
Patients must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for the treatment and the protocol
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/magnetic resonance imaging [MRI] of abdomen/pelvis, bone scintigraphy or NaF PET/CT)
Patients must not have had urothelial carcinoma in the prostate or upper urinary tract within the previous 24 months, or muscle invasive urothelial carcinoma of the bladder at any time; patients must have a computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis to rule out upper tract malignancy and intra-abdominal metastases within 90 days prior to registration
Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis demonstrating no evidence of nodal involvement or metastatic disease (magnetic resonance imaging [MRI] or computed tomography [CT] scan) within 90 days prior to registration; patients with T1 disease must have re-resection confirming =< T1 disease within 90 days prior to registration
Patients with evidence of extramedullary disease at diagnosis will have computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis to obtain baseline values within 28 days prior to registration
Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry
Evidence of disease progression:\r\n* 2 or more new lesions on bone scan or\r\n* Progressive disease on computed tomography (CT)/magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or\r\n* PSA progression consist of 3 PS rises, at least 2 weeks apart with the last value to be at least a 2 ng/ml
At least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or magnetic resonance imaging (MRI) images to define specific size and validate complete clinical and pathologic response
The study population will include women with a high preoperative suspicion of advanced primary epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (stage IIIC or IV) as determined by computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis planning to undergo exploratory laparotomy and surgical cytoreduction with the operative goal of this procedure to achieve optimal cytoreduction to less than 1 cm of residual disease
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; if an MRI is being obtained to verify eligibility, it is recommended that the MRI parameters follow the specifications detailed in the protocol so that the patient will not require a repeat MRI prior to treatment start
Patients must have T3/4 or N+ disease by magnetic resonance imaging (MRI) or endoscopic ultrasound
Magnetic resonance imaging (MRI) scans of the brain and spine must be completed within 21 days prior to patient registration; all MRI scans should be with and without gadolinium
Ability to tolerate magnetic resonance imaging (MRI).
Active central nervous system (CNS) metastases; subjects must undergo a head computed tomography (CT) scan or brain magnetic resonance imaging (MRI) within 28 days prior to registration for protocol therapy to exclude brain metastases if symptomatic or without prior brain imaging
Patients not able to have a magnetic resonance imaging (MRI) (due to pacemaker, claustrophobia, etc.)
Patients must have measurable (defined by at least 1 cm x 1 cm) contrast-enhancing disease by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment
Able to undergo a magnetic resonance imaging (MRI) scan and receive gadolinium-based contrast
At least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or magnetic resonance imaging [MRI])
In the expansion cohort: subjects must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; bone lesions are not considered measurable by definition
Bony metastatic lesions must be =< 8 cm in maximum dimension and evaluable on either a computed tomography (CT) or magnetic resonance imaging (MRI) scan; metastatic lesions in the spine must involve =< 3 contiguous vertebral bodies
Participants with known brain metastases may be enrolled in this study if radiation therapy and/or surgery have been completed with a minimum of 3 months of stable disease demonstrated on serial evaluation by computed tomography (CT) (with contrast enhancement) or magnetic resonance imaging (MRI); such participants must no longer require treatment with corticosteroids or enzyme inducing anti-epileptic medications for their central nervous system (CNS) disease
Documented progressive metastatic CRPC based on at least one of the following criteria:\r\n* Rise in PSA: a minimum of 3 rising levels, with an interval of at least 1 week between each determination; the last determination must have a value >= 1 ng/mL, obtained within 4 weeks of starting study drug\r\n* Measurable disease: new or progressive soft tissue disease on computerized tomography (CT) or magnetic resonance imaging (MRI) scans\r\n* Radionuclide bone scan: at least 2 new bone lesions, as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria
At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST version 1.1
Have undergone magnetic resonance imaging (MRI) for MB, a computerized tomography (CT) / metaiodobenzylguanidine (MIBG) scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month prior to first dose of study treatment
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI contraindicated) within 14 days prior to start of study drug; corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan; if steroids are added or the steroid dose is increased between the date of the screening MRI or CT scan and the start of treatment, a new baseline MRI or CT is required
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and initiation of study treatment, a new baseline MRI/CT is required
Contraindication to magnetic resonance imaging (MRI)
Post-operative computed tomography (CT) myelogram or magnetic resonance imaging (MRI) perfusion with evidence of separation of tumor and the spinal cord
Brain metastasis, unless previously treated with surgery or stereotactic radiosurgery and the disease has been confirmed stable (i.e., no increase in lesion size) for at least 6 weeks with two consecutive magnetic resonance imaging (MRI) scans using contrast prior to study day 1; enzyme inducing anticonvulsants are not allowed while patients are on study treatment
For patients who have received prior cranial radiation, no increase in corticosteroid dose in the week prior to the baseline brain magnetic resonance imaging (MRI)
The subject has had an assessment of all known non-CNS disease sites e.g., by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
At least 1 measurable lesion as defined by RECIST 1.1 on imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI])
Patients must have a baseline evaluation including history and physical examination with neurological evaluation and magnetic resonance imaging (MRI) of the brain (with and without gadolinium-based contrast), all completed within 30 days prior to initiation of treatment
Brain magnetic resonance imaging (MRI) with gadolinium within 4 weeks of study enrollment demonstrating the absence of brain metastases; if an MRI is medically contraindicated or if the patient refuses, a head CT with IV contrast is acceptable
All patients must have measurable disease documented by computed tomography (CT), magnetic resonance imaging (MRI), or nonmeasurable disease documented by physical exam within 28 days prior to registration
Participants with known spinal or distant metastases; patients with ependymoma, medulloblastoma or germinoma must have metastatic workup including spine magnetic resonance imaging (MRI) to rule out metastases
Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic resonance imaging of the brain or clinical progression)
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 28 days before the first dose of cabozantinib
Hepatocellular carcinoma (HCC) diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs 5 per the American College of Radiology [ACR’s] LIRADs criteria) by computed tomography (CT) or magnetic resonance imaging (MRI)
1-6 definitive intracranial lesions must be present on magnetic resonance imaging (MRI) of the brain
Has 1 or more discrete malignant lesions that are amenable to ?2 separate biopsies guided by one of the following modalities: visual inspection, ultrasound guidance, or cross sectional image guidance (computed tomography/magnetic resonance imaging [CT/MRI]).
Patients must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST v1.1.
The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST 1.1 to be deemed a target lesion.
Must be able to tolerate computed tomography (CT) and/or magnetic resonance imaging (MRI) with contrast
Locally advanced HCC as defined by: 1) tissue diagnosis OR 2) alpha-fetoprotein (AFP) > 400 ng/mL with compatible mass on contrast-enhanced imaging OR 3) compatible mass on dual phase computed tomography (CT) or dynamic contrast enhanced magnetic resonance imaging (MRI) demonstrating both arterial hypervascularity and delayed washout
Metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
Cytologically-confirmed LMD or radiologically detectable LMD defined as either/or:\r\n* A measurable lesion on contrast-enhanced magnetic resonance imaging (MRI) of either the brain or total-spine > 3 mm that has not been radiated within the last 3 months prior to commencement of study therapy\r\n* Positive CSF cytology
Tumor thickness is 4 mm or less (measured clinically and/or by computed tomography [CT] or magnetic resonance imaging [MRI] scan)
Five-twenty intracranial lesions must be present on magnetic resonance imaging (MRI) of the brain
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 that can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Experienced first unequivocal progression of tumor by magnetic resonance imaging (MRI) [as assessed via Radiologic Assessment in Neuro-Oncology (RANO) criteria within 3 months from the last dose of TMZ.
Participants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; bone lesions are not considered measurable by definition
Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions on magnetic resonance imaging (MRI)
Patient must have magnetic resonance imaging (MRI) confirming progressive disease
Metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan
Individuals with distant metastases or clinically or pathologically involved lymph nodes are ineligible; if suspected, they must be ruled out by computed tomography (CT), pelvic magnetic resonance imaging (MRI), or bone scan within 365 days of study entry
Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1
Presence of T1 gadolinium (Gd)–enhancing lesions (on magnetic resonance imaging [MRI]) suggestive of high-grade glioma
Inability to undergo magnetic resonance imaging (MRI) evaluation for treatment planning and follow-up
Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer (AJCC) staging, 7th edition\r\n* Staging workup must include: brain imaging (CT head or magnetic resonance imaging [MRI] brain) and PET/CT\r\n* Pleural effusions must have cytology to rule out malignant involvement unless too small to undergo thoracentesis per radiology
At least one lesion that can be accurately assessed at baseline by computed tomography (TC), magnetic resonance imaging (MRI) or X-ray, that is suitable for repeated measurement, OR
Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
Patients with known central nervous system metastases may be enrolled if they have received radiotherapy, do not require chronic steroid therapy, have had computed tomography or magnetic resonance imaging of the brain within 1 month of study entry that shows stable disease and they have no neurological symptoms other than low grade neuropathy.
Patients must have measurable disease according to RECIST criteria on anatomic imaging studies (computed tomography [CT] scan or magnetic resonance imaging [MRI])
Patients must have measurable disease (in 2-dimensions) on magnetic resonance imaging (MRI) scan of brain and/or spine to assess preliminary evidence of response
Patients must be able to have magnetic resonance imaging (MRI) scans
Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
Must be found to have locally advanced unresectable disease following standard chemotherapy and/or (+/-) radiotherapy as demonstrated with computed tomography (CT)/magnetic resonance imaging (MRI) and surgical evaluation
Subjects must be free of visible disease on imaging (computed tomography [CT], positron emission tomography CT [PETCT] or magnetic resonance imaging [MRI]) evaluating chest, abdomen, and pelvis within 28 days of enrollment on the study
Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on computed tomography [CT] scan and/or magnetic resonance imaging [MRI] of the abdomen and pelvis)
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI).
Has visceral metastases with >= 3 lung and/or liver metastases or individual lesion >= 2 cm, as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis within the last 8 weeks prior to randomization
Magnetic resonance imaging (MRI) pelvis, computed tomography (CT) pelvic, or bone scan for a PSA >= 0.2 ngs/ml may be done, based on the physician preference
Histologically proven adenocarcinoma of the lower rectum (lower border =< 6 cm from anal verge as assessed by pelvic magnetic resonance imaging [MRI]).
EXCLUSION - PARTICIPANT: Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [confirmed by computed tomography (CT) scan if CT used at prior imaging, or confirmed by magnetic resonance imaging (MRI) if MRI was used at prior imaging) for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
ARM I&II: Patients must have gadolinium magnetic resonance imaging (MRI) or contrast computed tomography (CT) with contrast within 28 days prior to starting treatment
Six or more metastases on diagnostic or treatment planning imaging, which include either computed tomography (CT) or magnetic resonance (MR) imaging.
Newly diagnosed brain metastases (metastases on post-contract magnetic resonance imaging [MRI] obtained within six weeks of study entry) deemed to be amenable to SRS\r\n* Tumor size limited to largest volume < 10 cc\r\n* Longest diameter < 3 cm\r\n* Cumulative volume of all tumors =< 15 cc
Metastatic disease documented by at least one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI)
Is able to have magnetic resonance imaging (MRI) with contrast of the brain
Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is ? 10 mm in longest diameter by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI); the total volume of the tumors must be less than 50% of the liver volume
INCLUSION - ENROLLMENT: cT1-2N0 on clinical staging (verified to have no suspicious axillary or internal mammary nodes on magnetic resonance imaging [MRI] or ultrasound)
Evidence of metastasis by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histologic confirmation
Documented first or second recurrence of glioblastoma (GBM) by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 21 days of randomization per Response Assessment for NeuroOncology (RANO) criteria.
Brain magnetic resonance imaging (MRI) (or CT if contraindication to MRI) within the last 60 days showing no evidence of metastatic disease
Is unable (due to existent medical condition) or unwilling to have a contrast enhanced magnetic resonance imaging (MRI) of brain
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; radiographic tumor assessment performed within 28 days before treatment; target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 non-biopsied, non-irradiated lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).
A diagnostic magnetic resonance imaging (MRI) brain or computed tomography (CT) head demonstrating the presence of 1-4 solid tumor brain metastases and lesion to be resected no more than 5 cm in any direction, performed within 30 days prior to stereotactic radiosurgery. If multiple lesions are present, then the total brain metastases volume can be no more than 30 cm^3 excluding the lesion to be resected
Subject has at least 1 measurable lesion per RECIST v1.1 criteria by computed tomography (CT) scan or magnetic resonance image (MRI).
Must be tumor-free as assessed by the Investigator and validated by either computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain and chest, abdomen, and pelvis and a bone scan ?28 days from randomization.
Measurable disease detected by imaging exam (CT or MRI).
Phase I patients must have measurable contrast-enhancing disease (defined as at least 1 cm x 1 cm) by magnetic resonance imaging (MRI) imaging within 21 days prior to starting treatment (patients may have gross total resection, but should have measurable disease post-operatively); patients must be able to undergo MRI of the brain with gadolinium
Metastatic disease evident on computed tomography (CT) or magnetic resonance imaging (MRI) staging scans
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Unicentric American Joint Committee on Cancer (AJCC) 7th edition T1N0M0 tumor measuring no greater than 2.0 cm in longest dimension on initial imaging with either breast magnetic resonance imaging (MRI) and/or mammogram
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Patient must have recent imaging (computed tomography [CT] or magnetic resonance imaging [MRI], as appropriate) within 4 weeks of trial enrollment, demonstrating measurable disease as defined by RECIST 1.1.
Radiographic confirmation of oligometastatic diagnosis via bone scan validated by either computed tomography (CT) scan or magnetic resonance imaging (MRI) within the past 90 days
Unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or have documented recurrent glioma on diagnostic biopsy
Patients must be able to undergo magnetic resonance imaging (MRI) scan with gadolinium contrast for treatment planning
Meet eligibility requirements for SRS: able to get magnetic resonance imaging (MRI), lesion must not be abutting optic apparatus or brainstem, and must be able to be secured and positioned in a stereotactic U-frame mask
Patients who cannot safely undergo magnetic resonance imaging (MRI) due to non-MRI compatible pacemaker, or other reason
Patients with a parenchymal brain lesion thought to be consistent with active lymphoma on screening computed tomography/magnetic resonance imaging (CT/MRI); of note, patients with cerebral spinal fluid (CSF) involvement alone are not excluded
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans).
Subject has histological verification of tumor either at the time of diagnosis or recurrence. Subjects with DIPG are exempt from histologic verification if they have typical Magnetic resonance imaging (MRI) findings of DIPG
Evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on computed tomography (CT) or magnetic resonance imaging (MRI) and/or evaluable FDG-avid lesions on PET)
Patients must have imaging (magnetic resonance imaging [MRI] or computed tomography [CT] abdomen liver protocol) confirmed hepatocellular carcinoma. Patients cannot have metastatic HCC
Patient can’t have magnetic resonance imaging (MRI) scan
Patients with absolute contraindication to magnetic resonance imaging (MRI) imaging are not eligible for the study
Measurable disease, even after resection of applicable lesion for TIL harvest; defined as >= 1 lesion that is >= 10 mm in one dimension by computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers on clinical exam
Measurable disease by RECIST v1.1 criteria (tumor >= 1 cm in longest diameter on axial image on computed tomography (CT) or magnetic resonance imaging (MRI) and/or lymph node(s) >= 1.5 cm in short axis on CT or magnetic resonance imaging [MRI]) on baseline imaging
Evidence of metastatic disease to the bone seen on most recent bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
Have an enhancing mass on magnetic resonance imaging (MRI) amenable to > 90% resection of contrast-enhancing tumor (as determined by the neurosurgeon pre-operatively) and histological diagnosis of glioblastoma from a prior stereotactic biopsy
Patients with inability to complete brain magnetic resonance imaging (MRI) studies with contrast
Has measurable disease as defined by RECIST 1.12 on computed tomography (CT) or magnetic resonance imaging (MRI) and as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Gross disease apparent on imaging (magnetic resonance imaging [MRI] or computed tomography [CT])
A magnetic resonance (MR) scan must be obtained within 30 days of enrollment and must demonstrate an enhancing mass without significant mass effect; tumors must be less than approximately 32 cc in total volume, as assessed by the principal investigator (PI) based on pre-enrollment magnetic resonance imaging (MRI); the lesion must be stereotactically accessible
Participants must have locally advanced rectum cancer where primary resection without chemoradiotherapy (CRT) is unlikely to achieve clear margins as defined by magnetic resonance imaging (MRI), with no metastatic disease, as assessed by independent review.
Unifocal tumor =< 2 cm based on contrast-enhanced prone-breast magnetic resonance imaging (MRI)
As defined on magnetic resonance imaging (MRI), target lesion must be at least 10 mm distance from skin (defined as volume encompassing first 3 mm from breast surface)
Patients must have at least one lesion that is not within a previously radiated field and that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scans per RECIST version 1.1; bone lesions are not considered measurable
(For Cohort A) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST). (For cohort B) Clinical or radiologic primary tumor size of at least 1.5 cm prior to enrollment onto protocol 2014-0185 (ARTEMIS). Primary tumor of at least 1.0 cm or evidence of continued lymph node involvement by imaging (ultrasound or magnetic resonance imaging [MRI]) after adriamycin-based neoadjuvant therapy
The primary tumor must be measurable by an imaging modality prior to treatment; this imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery; such imaging modalities may include ultrasound, computed tomography (CT), mammography, or magnetic resonance imaging (MRI); MRI will be the preferred imaging modality if available; all imaging will be performed per standard of care at the discretion of the treating physicians
Measurable disease: subjects must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
Be able to undergo a brain magnetic resonance imaging scan
Active disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
All subjects must have at least 2 distinct lesions as documented by a complete physical examination and imaging studies within 4 weeks prior to randomization; imaging studies must include a CT scan of the involved disease sites and all known sites of resected disease and brain magnetic resonance (MRI) or CT (brain CT allowable if MRI is contraindicated or if there is no known history of resected brain lesions)
Patients with untreated/active brain metastases as documented by magnetic resonance imaging (MRI) within 2 months of study enrollment
Patients must have measurable disease according to the standard RECIST version 1.1\r\n* NOTE: computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess the measurable disease must have been completed with 28 days prior to the study drug initiation
>= 1 evaluable site of disease measuring >= 1.5 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) as measured per Response Evaluation Criteria in Solid Tumors (RECIST)
Bone disease documented by either: a positive bone scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI); or biopsy proven bony metastases
Able to undergo brain magnetic resonance imaging (MRI) with and without contrast without requiring general anesthesia
At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.
COHORT 2 (ON PROGRESSION OF SORAFEINIB): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on computed tomography/magnetic resonance imaging (CT/MRI); prior surgery or local therapy within 4 weeks prior to cycle 1 day 1, with the exception of palliative radiation therapy to the bone
Subjects must have metastatic disease detectable by either bone scan or cross sectional imaging by CT or magnetic resonance imaging (MRI) as per the PCWG3 guidelines
Patients unable to undergo magnetic resonance imaging (MRI) of the spine
Chest imaging (x-ray, CT or magnetic resonance imaging [MRI]) negative for metastasis no more than 6 weeks prior to the date of RPLND
Known active metastases to the brain, spinal cord or leptomeninges unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks of first study treatment as documented by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging and having no ongoing requirement for steroids
Magnetic resonance imaging (MRI) findings consistent or with a histologically confirmed newly diagnosed GBM that has not been treated and would benefit from further surgical resection
FOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record
For diseases other than CLL, LPL, and HCL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measureable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
Creatinine within normal institutional limits OR according to institutional magnetic resonance imaging (MRI) policy
Measurable disease by RECIST v1.1 criteria (tumor >= 1 cm in longest diameter on axial image on computed tomography [CT] or magnetic resonance imaging [MRI] and/or lymph node(s) >= 1.5 cm in short axis on CT or MRI) on baseline imaging
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Subjects must have suspected high grade glioma by magnetic resonance imaging (MRI)
Medical contraindication to undergoing magnetic resonance (MR) imaging
Clinical stage T3 or less as demonstrated by computed tomography (CT)/magnetic resonance imaging (MRI) will be selected as the prostate is resectable
Locally advanced rectal cancer determined by any of the following features\r\n* Fixed or immobile tumor on physical exam and/or\r\n* T3 disease with invasion through the muscularis propria as defined by transrectal ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI)\r\n* T4 disease with invasion of adjacent structures such as pelvic sidewall, sacrum, pelvis, bladder and/or prostate as determined appropriate imaging modalities such as ultrasound, CT or MRI\r\n* Any T with + N on CT scan/MRI or transrectal ultrasound
Patients must have potentially resectable pancreatic carcinoma and have agreed to undergo surgical resection at Monroe Dunaway (MD) Anderson Cancer Center if operable; they will have undergone staging (physical examination, contrast enhanced computed tomography [CT] or magnetic resonance imaging [MRI] [if CT contraindicated] to determine resectability)
Unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes
No evidence of metastasis on computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis within 120 days prior to registration
A contrast-enhanced magnetic resonance imaging (MRI) scan showing >= 4 treatable brain metastases
Patients with evidence of an acute intracranial or intratumoral hemorrhage on computed tomography (CT) or magnetic resonance imaging (MRI) are not eligible (patients with evidence of resolving hemorrhage will be eligible)
The primary tumor must be >= 2.0 cm in size and/or have biopsy proven axillary nodes that are >= 2.0 cm in size by mammography, ultrasound, or magnetic resonance imaging (MRI)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
All patients positive for invasion must have imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI]) documenting normal upper urinary tracts and absence of locally advanced bladder cancer within 60 days prior to study registration
Patient must be able have a magnetic resonance imaging (MRI) of the brain for treatment planning
Patients unable to have IV contrast for computed tomography (CT) and MRI imaging
Magnetic resonance (MR) imaging of the brain (performed within 14 days of enrollment) must demonstrates no evidence of diffuse leptomeningeal spread beyond the primary relapse site in posterior fossa and no obstruction of cerebrospinal fluid flow (CSF)
Patients with evidence of metastatic spinal disease by magnetic resonance imaging (MRI) are NOT eligible for either Stratum
Patients must be willing to undergo a radiologic scan (computed tomography [CT] or magnetic resonance imaging [MRI], depending on organ involved) after last drug dose and prior to minimally-invasive surgery
Known active CNS metastases and/or carcinomatous meningitis a. To be eligible for the study treatment, subjects must have stable disease ? 1 month, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications.
Contraindication to magnetic resonance (MR) imaging
Histologically confirmed systemic malignancy with gadolinium contrast-enhanced magnetic resonance imaging (MRI) scan demonstrating 1-5 newly diagnosed intraparenchymal brain metastases
Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes < 2 cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography
Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan syndrome, PFO, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by computerized tomography [CT] scan with contrast or magnetic resonance imaging [MRI]).
At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (or magnetic resonance imaging [MRI] suitable for assessment as per RECIST 1.1. The baseline scan must be obtained within 28 days prior to the first dose of olaparib.
Patients must have measurable lesion in the brain or spine that is >= 3 mm seen on magnetic resonance imaging (MRI) with contrast; NOTE: contrasted pre-treatment MRI scan must be obtained =< 21 days prior to stereotactic radiosurgery treatment
At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI]) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion >= 10 mm in longest diameter
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans)
Measurable disease as defined by at least one tumor that is measurable in two dimensions on CT or magnetic resonance imaging (MRI) scan (minimum size 1.0 cm for at least one lesion)
Stage IV metastatic disease with intracranial disease visible with magnetic resonance image (MRI)
Has staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within 4 weeks prior to treatment initiation
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated), and if the patients with CNS metastases are not taking prednisone > 10 mg or equivalent daily
No evidence of extraprostatic disease on 3T multiparametric pelvic magnetic resonance imaging (MRI)
Recurrence of glioblastoma (GBM) since completion of most recent therapy; recurrence must be documented by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 21 days prior to entering the study per Response Assessment in Neuro-Oncology (RANO) criteria
Radiographic evidence by magnetic resonance imaging (MRI) of brain metastasis (if patient is unstable to tolerate contrast, an MRI without contrast is acceptable)
Diagnosis of biopsy proven stage I-IIIB (cT1-3, N0-2, M0) adenocarcinoma of the rectum; staging must also be based on multidisciplinary evaluation including magnetic resonance imaging (MRI) and/or endorectal ultrasound
Presence of any contraindications to magnetic resonance imaging (MRI) scanning
Patients must have measurable disease, by computed tomography (CT) or magnetic resonance imaging (MRI) per modified RECIST criteria for mesothelioma; radiographic tumor assessment must be performed within 28 days prior to the first treatment
Clinical stage =< T3a based on digital rectal exam and/or =< T3a based on magnetic resonance imaging (MRI) (if done); N0-Nx; M0-Mx (American Joint Committee on Cancer [AJCC] 7th edition)\r\n* T-stage and N-stage will be determined by physical exam including a digital rectal exam and available imaging studies (computed tomography [CT], and/or MRI of the pelvis); for MRI, extracapsular extension is permitted; to distinguish blood from tumor the ideal study would be to acquire T2, T1 noncontrast and T1 dynamic contrast enhanced sequence, although this is not required\r\n* M-stage determined by physical exam, CT of abdomen and pelvis with contrast, and bone scan
No evidence of > grade 1 active CNS hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
Histologically confirmed primary invasive adenocarcinoma of the breast with the size of the primary tumor being at least 1.5 cm, or at least 1 biopsy confirmed involved lymph node > 1.5 cm, on imaging by either mammography, ultrasound or breast magnetic resonance imaging (MRI)
Localized spine metastasis from the cervical (C)1 to lumbar (L)5 levels with documented epidural cord compression by a screening imaging study (magnetic resonance imaging [MRI] or computed tomography [CT] myelogram); site may have a maximal involvement of 2 contiguous vertebral bodies; patients with other visceral metastasis, and radioresistant tumors (including soft tissue sarcomas, melanomas, and renal cell carcinomas) are eligible
Patients must have disease that can be measured and followed by mammogram and/or breast ultrasound (in special cases a dedicated breast magnetic resonance imaging [MRI] may be clinically indicated); the target lesion must not have been previously irradiated
Patient has no contraindications to magnetic resonance imaging (MRI) scanning with intravenous contrast
Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria; the criteria specifies computed tomography (CT) or magnetic resonance imaging (MRI) intense arterial uptake followed by “washout” of contrast in the venous-delayed phases; any atypical lesions must be confirmed by biopsy
Documented disease progression (as per RECIST v1.1) before study entry; for patients with osteosarcoma, this progression will be confirmed by central review on the basis of two CT scan or magnetic resonance imaging (MRI) obtained at less than 6 months in the period of 12 months prior to inclusion
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks prior to enrollment as documented by magnetic resonance imaging (MRI) or computed tomography (CT) imaging; treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 4 weeks prior to enrollment as documented by MRI or CT imaging
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])
Must have evaluable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan, according to RECIST 1.1 (subjects with measurable disease per RECIST 1.1 or radiographically visible and evaluable disease). Subjects with only ascites or pleural effusion are excluded.
Rectal cancer originally staged as T1, T2, or T3, node negative (N0) or node positive (N1, N2) by pelvic magnetic resonance imaging (MRI)
Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:\r\n* Histologically confirmed\r\n* Magnetic resonance imaging (MRI) or computerized tomography (CT) findings consistent with hepatocellular carcinoma\r\n* Alpha fetoprotein (AFP) > 400 ng/mL AND evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI
Inability to undergo magnetic resonance imaging
Eligible for contrasted magnetic resonance imaging (MRI) on initial evaluation with glomerular filtration rate (GFR) >= 60 ml/min; a diagnostic MRI ordered within 60 days of diagnosis will be considered an acceptable alternative and will not be repeated
Known active CNS metastases and/or carcinomatous meningitis • To be eligible for the study treatment, subjects must have stable disease ? 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications
Patient must have measurable disease\r\n* Tumor size at least >= 5 cm in the longest diameter as measured by computed tomography (CT) scan or magnetic resonance imaging (MRI) for which radiation is feasible
Evidence of metastatic disease: minimum imaging required Computed tomography scan (CT) / Magnetic Resonance Imaging (MRI) and Whole Body Bone Scan (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
Adult patients with locally advanced or recurrent orbital or periorbital BCCA, or a medial canthal BCCA that threatens the lacrimal drainage system, as noted by clinical exam, clinical photography, computed tomography (CT) or magnetic resonance imaging (MRI) and positive biopsy, and who do not have a contraindication to either surgical or vismodegib treatment\r\n* Treating physician to assess whether the patient is a candidate for vismodegib treatment
Participants must have evaluable or measurable disease based on RECIST 1.1 using computed tomography (CT)/magnetic resonance imaging (MRI).
Clinically confirmed brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI) criteria; if there is evidence of extra-cranial metastatic disease, it is preferable if that the lesions be pathologically confirmed and reviewed by a University of Utah or Huntsman Cancer Hospital pathologist if the initial review was done at an outside facility
Surgery: at least 2 weeks following surgery including brain and spine provided post-operative magnetic resonance imaging (MRI) shows no active bleeding
Patients may not be on systemic steroids within 4 weeks of enrolling on study with the exception of physiologic replacement doses (for instance in the case of adrenal insufficiency) or steroid premedication for baseline magnetic resonance imaging (MRI) and/or computed tomography (CT) in the case of subjects with known contrast dye allergies
Patients must have evidence of MIBG avid disease as determined by diagnostic MIBG scan obtained within 4 weeks of MIBG infusion; at least one MIBG avid target lesion that can be evaluated for response must be present at study entry; computed tomography (CT)/magnetic resonance imaging (MRI) evaluation of all sites of disease must be completed within 4 weeks of MIBG infusion
Active central nervous system (CNS) involvement by malignancy (patients with known positive cerebrospinal fluid [CSF] cytology or parenchymal lesions visible by computed tomography [CT] or magnetic resonance imaging [MRI])
Imaging studies can include but is not limited to the following: ultrasound, CT of pelvis and abdomen and magnetic resonance imaging (MRI) of pelvis/prostate and abdomen\r\n* The ultrasound, MRI or CT based volume estimation of the patient’s prostate gland should not be greater than 80 grams (Repeat measurement after hormone downsizing allowed)\r\n* Clinically negative lymph nodes, within 90 days of study enrollment, established by imaging (abdominal and pelvic CT or MRI) OR by nodal sampling OR by dissection; nodes > 2.0 cm should be biopsied; patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are < 2.0 cm in the short axis\t\r\n* MRI pelvis/prostate feasible for staging and planning\r\n* Patients with contraindications to MRI are not eligible
Clinically negative lymph nodes as established by abdominal-pelvic computed tomography (CT), no more than 90 days prior to registration; CT only for clinical classification of > T3 (with contrast if renal function is acceptable; a non-contrast CT is permitted if the patient is not a candidate for contrast), magnetic resonance imaging (MRI), nodal sampling, or dissection; patients with lymph nodes equivocal or questionable by imaging are eligible if those nodes are < 1 cm in short axis diameter
Patients must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI), and are not included in any prior field of radiation given to treat B-NHL\r\n* In patients with CLL, circulating lymphocytes >= 5,000 / mm^3\r\n* In patients with WM/LPL, measurable serum monoclonal immunoglobulin M (IgM)
Clinical American Joint Committee on Cancer (AJCC) 7th edition stage T2N1M0, T3N0M0 or T3N1M0 based on physical examination, CT scan chest/abdomen/pelvis, and pelvic magnetic resonance imaging (MRI) or endorectal ultrasound
Imaging by magnetic resonance imaging (MRI), ultrasound and/or mammogram and physical exam to document lesions size must be performed within 30 days of study entry
Able to undergo brain magnetic resonance imaging (MRI) with and without contrast
Centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
No pelvic nodal metastases (based on computed tomography [CT] or magnetic resonance imaging [MRI] findings)
Known leptomeningeal disease or evidence of prior or current metastatic brain disease (routine screening with central nervous system [CNS] imaging studies [computed tomography (CT) or magnetic resonance imaging (MRI)] is required only if clinically indicated)
Subjects with brain metastasis are excluded from this study, and all patients should have brain imaging (either magnetic resonance imaging [MRI] brain or CT brain with contrast) prior to enrollment
Must have presence of an enhancing solid renal mass =< 3.0 cm on computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have a computed tomography (CT) (preferred) or magnetic resonance imaging (MRI) scan of the chest, abdomen, and pelvis within 28 days of enrollment
Unable to undergo magnetic resonance imaging (MRI) imaging
Prospective participant is unable to undergo a magnetic resonance imaging (MRI) with contrast agent
Gross disease must be unifocal on mammogram (mammo)/magnetic resonance imaging (MRI) imaging
The subject must have a baseline brain magnetic resonance imaging (MRI) scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib\r\n* Patients receiving glucocorticoids must be on a stable dose of glucocorticoids during the 5 days prior to the baseline brain imaging
If consenting to participate in the optional PET/MR imaging sub-study, the patient must be able to tolerate PET/magnetic resonance imaging (MRI) with intravenous contrast administration and must complete the applicable MRI screening evaluation form
Diagnostic imaging magnetic resonance imaging (MRI) and/or computed tomography (CT) of the area to be treated within 8 weeks of any treatment; baseline bone marrow biopsy and bone scan (with 99m-Tc-diphosphonate or metaiodobenzylguanidine [MIBG] scan [131I-MIBG or 123I-MIBG]) from time of original diagnosis is required
Clinically negative lymph nodes as established by imaging (pelvic ± abdominal computed tomography [CT] or magnetic resonance imaging [MRI]), (but not by nodal sampling, or dissection) within 90 days prior to registration
Residual lesion must be >= 1.0 cm in diameter as determined by magnetic resonance imaging (MRI)
The subject has had an assessment of all known disease sites e.g, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Pancreas protocol computed tomography (CT) and/or magnetic resonance imaging (MRI) if required for further clarification of disease tissue planes within 4 weeks of registration
Measurable disease on magnetic resonance imaging (MRI) scan
Contraindication to both contrast enhanced magnetic resonance imaging (MRI) and contrast enhanced computed tomography (CT) (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
Patients must have had a bilateral diagnostic mammogram within 6 months of registration, and may also have a targeted sonography of the breast and/or ipsilateral axilla and magnetic resonance imaging (MRI) if clinically indicated
Radiographic evidence of metastatic disease; computed tomography (CT) and bone scan must be performed with 21 days (+ 7 days) of registration; magnetic resonance imaging (MRI) of brain can be performed within 6 months prior to registration
Participants must have histologically or radiological evidence of stage I (T1N0M0) renal cell carcinoma with a size no larger than 8 cm in greatest dimension measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan
RECIPIENT: Active central nervous system (CNS) involvement by malignancy (patients with known positive cerebrospinal fluid [CSF] cytology or parenchymal lesions visible by computed tomography [CT] or magnetic resonance imaging [MRI])
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) of the brain must be performed preoperatively and postoperatively prior to the initiation of radiotherapy; the postoperative scan must be performed within 28 days prior to registration; (contrast enhanced brain computed tomography [CT] is allowed if MRI is contraindicated)
Any contraindication for undergoing magnetic resonance imaging (MRI)
Local, locally advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Measurable disease by computed tomography (CT) or similar (e.g. magnetic resonance imaging [MRI]) criteria (> 1.5 cm)
Contrast computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain negative for central nervous system metastases within 30 days of treatment
All patients must have greater than 3 but less than or equal to 15 metastatic lesions seen on a contrast enhancing magnetic resonance imaging (MRI) scan obtained not less than one month prior to study enrollment; patients who are found to have up to 20 metastatic lesions at the time of treatment planning (on volumetric MRI once the head frame is in place) may still participate in the trial
Cranial magnetic resonance imaging (MRI) or contrast computed tomography (CT) must have been performed within 21 days of study entry; the use of MRI rather than CT is preferred; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; if the surgical procedure was a resection, cranial MRI or contrast CT performed within 96 hours of resection is preferred but not required; if the surgical procedure was a biopsy only, a head CT within 96 hours of the biopsy is acceptable; patients without measurable or assessable disease are eligible
All patients must undergo pre-treatment evaluation of tumor extent prior to study entry through imaging studies and clinical examinations, including computed tomography (CT) and/or magnetic resonance imaging (MRI) of skull base, brain and neck within 28 days prior to study entry; physical examination +/- nasal endoscopy within 28 days prior to study entry; and CT of the chest within 60 days prior to study entry
Baseline imaging in the form of CT chest, abdomen, pelvis with oral and intravenous contrast within 28 days of study entry; for patients with a contrast allergy, choice of alternative body imaging will be at the discretion of the investigator or his designee; magnetic resonance imaging (MRI) of the brain is only needed if clinically indicated
Consensus of diagnosis must be reached by a multidisciplinary pediatric neuro-oncology team by considering both clinical evidence and magnetic resonance imaging (MRI) presentation; tissue diagnosis is not required
There must be measurable disease on magnetic resonance imaging (MRI)
Patients must have no evidence of metastatic disease based on routine imaging (computed tomography [CT] or magnetic resonance imaging [MRI] of the chest/abdomen/pelvis, bone scan, etc.)
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan should be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; measurable disease is NOT required\r\n* Note: MRI is the preferable imaging method; CT scan may be used in cases where an MRI cannot be obtained
Magnetic resonance imaging (MRI) with gadolinium should be obtained within 21 days prior to beginning treatment; patients without measurable disease are eligible; participants must be able to undergo MRIs (computed tomography scans [CTs] are not allowed for response assessment on study)
Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).
Measurable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI)
At least one measurable viable tumor in the liver, ?1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)
No evidence of metastatic disease in the brain, spine or cerebrospinal fluid (CSF); assessments must include magnetic resonance imaging (MRI) imaging of the brain and spine with and without contrast and a lumbar puncture for CSF cytology
CT, magnetic resonance imaging (MRI), or PET/CT imaging of the chest, abdomen, and pelvic regions within 42 days prior to registration (for stage I patients, posterior-anterior [PA] and lateral chest x-ray is sufficient for chest imaging)
Evidence of a new intracranial or intratumoral hemorrhage that is larger than a punctuate size on baseline magnetic resonance imaging (MRI) obtained within 14 days prior to study registration
Imaging studies: brain magnetic resonance imaging (MRI) before start of protocol therapy; images must include T1, T1 with gadolinium, T2, and fluid attenuated inversion recovery (FLAIR) sequences
Inability to tolerate periodic magnetic resonance imaging (MRI) scans or gadolinium contrast
Magnetic resonance imaging (MRI) scans of the brain and spine must be completed within 14 days of patient registration; all MRI scans should be with and without gadolinium
Newly diagnosed brain metastases (four or fewer by postcontrast magnetic resonance imaging [MRI] obtained within six weeks of study entry)
Active central nervous system (CNS) involvement by malignancy (patients with known positive cerebrospinal fluid [CSF] cytology or parenchymal lesions visible by computed tomography [CT] or magnetic resonance imaging [MRI]); except in the case of viral associated malignancies in which case the patient may benefit from the transplant to control the malignancy
Tumor volume occupies less than 50% of liver by volume as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) scan within 4 weeks of treatment
Patients with evidence on prior imaging (bone scan, CT, or MRI) suggestive of disseminated disease will not be eligible (imaging not required for eligibility)
Evidence of distant metastasis; (determined by computed tomography [CT] scan, magnetic resonance imaging [MRI], and/or bone scan prior to the simulation appointment; imaging results from University of Pennsylvania Health System [UPHS] will supersede results from similar scans from an outside facility)
Patients must have an magnetic resonance imaging (MRI) or computed tomography (CT) of the head showing no central nervous system (CNS) metastases within 6 weeks of study entry
Must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI)
Confirmed presence of hepatocellular carcinoma indicated on computed tomography, magnetic resonance, or other imaging techniques within 3 months prior to screening
Contraindication to magnetic resonance imaging (MRI) contrast agents
There must be measurable contrast-enhancing progressive or recurrent GBM (single or multiple lesions) by magnetic resonance imaging (MRI) imaging with an interval of greater than or equal to 6 months between recurrence and completion of prior radiotherapy; while there is no defined maximum tumor volume for eligibility in this study, patients with diffuse, multifocal recurrences may be excluded at the discretion of the study principle investigator (PI); there must be an MRI performed within 4 weeks prior to any therapy
Patients are excluded if they are unable to obtain a Magnetic resonance imaging (MRI) scan for any other reason.
Documented malignant biliary obstruction requiring endoscopic retrograde cholangiopancreatography (ERCP) guided stenting; documentation of malignancy will be made before the scheduled procedure and rapid pathology readings will not be used as a documentation of malignancy; documentation of malignancy may be in the form of;\r\n* Histology (bile duct biopsy)\r\n* Liver or pancreas fine needle aspiration (FNA), biliary\r\n* Brush cytology\r\n* Malignant ascites\r\n* Peritoneal biopsy\r\n* Cross sectional imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) and abnormal liver function tests (findings compatible with obstruction)
Measurable disease by computed tomography or magnetic resonance imaging based on RECIST 1.1 as determined by site radiology.
Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI)
At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST (RECIST version 1.1) and no older than 28 days before start of the study treatment. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
High-quality cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) performed within 4 weeks prior to enrollment
No evidence of metastatic disease or nodal disease as determined by radionuclide bone scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological lymph nodes must be less than 20 mm in the short (transverse) axis.
At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
Must have measurable disease per RECIST 1.1 as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). a. Lesion/s deemed accessible to biopsy for both before and on-treatment biopsies.
Clinical T1N0M0 (=< 7 cm) renal mass as measured on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
? 5 metastases on conventional imaging with computed tomography (CT)/magnetic resonance imaging (MRI) of the abdomen/pelvis and whole body bone scan
For diseases other than LPL and CLL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measurable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
BLADDER: Patients may not have evidence of metastatic disease on baseline computed tomography (CT) or magnetic imaging resonance of the chest, abdomen, or pelvis
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib
Contraindication for undergoing magnetic resonance imaging (MRIs)
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT]).
Inability or unwillingness to have magnetic resonance imaging (MRI) scans performed (e.g. cardiac pacemaker-dependent)
All patients must have measurable disease by imaging defined as tumor that can be measured >= 10 mm with multiparametric magnetic resonance imaging (MRI) (primary modality of imaging) or computed tomography (CT) (as an alternative) or >= 10 mm by caliper on physical examination
Patients must have magnetic resonance imaging (MRI) within 21 days of starting treatment; patients must be able to tolerate MRI
Participants with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of progressive disease based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging or histopathology
Inability to undergo magnetic resonance (MR) imaging to assess disease status
Measurable or evaluable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version (v)1.1
Patients must be able to undergo magnetic resonance imaging (MRI) of the brain with gadolinium
Patients must have localized disease with a primary tumor >= 5 cm by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by computed tomography (CT) or magnetic resonance imaging (MRI) scan, analysis of cerebrospinal fluid or neurological exam; patients with primary glioblastoma multiforme are excluded
Have been more than 1 month and less than 3 months after the completion of planned adjuvant chemotherapy and no definitive evidence of recurrent disease on screening imaging (computed tomography [CT] or magnetic resonance imaging [MRI]); if adjuvant treatment is not planned, then patients must be more than 1 month and less than 3 months after resection of their pancreas cancer
Patients must meet both of the first two conditions, OR the third:\r\n* Clinical findings consistent with a presumed new diagnosis of diffuse midline glioma (DMG) in the opinion of the treating neuro-oncologist, AND\r\n* Brain magnetic resonance imaging (MRI) findings consistent with a new diagnosis of DMG based on multidisciplinary consensus after review of imaging \r\n* OR, recurrent DMG requiring tumor resection or biopsy
Metastatic disease as demonstrated by bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI) of the pelvis, or chest x-ray
Documented recurrence by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 28 days of entry in to the trial as per Response Assessment Criteria for High-Grade Gliomas (RANO) criteria
Computed tomography (CT) or magnetic resonance imaging (MRI) within 14 days prior to start of study therapy
Patients must have histologically or cytologically confirmed malignancy (not leukemia or lymphoma); there must be metastatic brain disease apparent on magnetic resonance imaging (MRI) which offers a medical indication for brain radiation
Magnetic resonance imaging (MRI) performed within 4 weeks of trial enrollment
Evidence of leptomeningeal disease by magnetic resonance imaging (MRI) and/or cerebrospinal fluid (CSF) cytology
Patients must have a brain magnetic resonance imaging (MRI) or computed tomography (CT) (with and without contrast) that is free of active metastases; metastases that have been treated with radiation or surgical resection, are stable for at least 4 weeks and do not require steroids are eligible
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator’s opinion, could compromise the patient’s safety, or put the study at undue risk; patients with suspicious radiologic evidence of aspergillosis infection (i.e., chest computed tomography [CT] and/or brain magnetic resonance imaging [MRI]) will not be eligible unless confirmatory laboratory testing of beta-D glucan and aspergillus antigen are negative
Assessable disease with a positive bone scan and/or measurable disease on computed tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and pelvis
Arm 1 patients must have measurable (defined by at least 1 cm x 1 cm) contrast-enhancing disease by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment
Patients who cannot undergo brain magnetic resonance imaging (MRIs)
If applicable, patients must be off bevacizumab therapy for 30 days before the baseline magnetic resonance imaging (MRI) is obtained
Must have measurable disease by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Subjects who have received radiotherapy to tumor lesions that would be chosen as target lesions (measurable disease) within 4 weeks before the start of treatment, except if there is objective evidence of progression of the lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the prior radiotherapy and the screening CT or magnetic resonance imaging (MRI) scan; palliative radiotherapy to non-target lesions is allowed at the investigator’s discretion
Radiologically confirmed metastatic brain lesion by magnetic resonance imaging (MRI)
Patients must have metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan; measurable disease is not necessary for inclusion
Patients must be able to tolerate computed tomography (CT), magnetic resonance imaging (MRI) or PET imaging including contrast agents
Known contraindication to enhanced magnetic resonance imaging (MRI) and computed tomography (CT) scan
Solid tumor patients must be off corticosteroids prior to registration; if GBM patient is receiving corticosteroids, patient must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline magnetic resonance imaging (MRI) or computed tomography (CT); if steroids are added or the steroids dose is increased between the date of the screening MRI or CT and the start of treatment, a new baseline MRI or CT is required
Highly suspicious magnetic resonance imaging (MRI) or cerebrospinal fluid (CSF) evidence of leptomeningeal metastases, unless all measurable disease is localized and SRS is considered the treatment of choice
Patient is unable to undergo a magnetic resonance imaging (MRI)
Histologically confirmed cancer with measurable or evaluable brain metastases by computed tomography (CT) or magnetic resonance imaging (MRI); MRI is preferred, but a CT scan is acceptable for patients that are unable to have an MRI
Computerized tomography (CT) urogram or magnetic resonance imaging (MRI) urogram; if urogram protocol not available or contrast allergy/poor renal function preclude such imaging, then noncontrast CT or MRI of the abdomen/pelvis within 45 days of study entry will suffice
Unresectable by radiographic criteria (pancreas protocol computed tomography [CT] or magnetic resonance imaging [MRI]) or exploration within 30 days prior to registration
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen or pelvis
Pretreatment brain CT with contrast or brain magnetic resonance imaging (MRI) to rule out metastases
Patients must be free of brain metastasis by contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) scans within 4 weeks prior to enrollment; if known to have prior brain metastases, must not have evidence of active brain disease after definitive therapy (surgery, radiation therapy or stereotactic radiosurgery) on two successive MRI evaluations at least 3 months apart (one of which is =< 4 weeks prior to starting the study drugs)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
At screening, patients with =< 3 untreated central nervous system (CNS) metastases may be included provided none of the untreated lesions are > 1 cm in greatest dimension, and there is no peri-tumoral edema present on brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] if MRI is contraindicated)
Contraindication for magnetic resonance imaging (MRI)
Evidence of leptomeningeal disease by magnetic resonance imaging (MRI) and/or cerebrospinal fluid (CSF) cytology
Patients must have clear residual disease, defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) OR diffuse leptomeningeal disease OR clear MRI evidence of disease that may not be measurable in two perpendicular diameters
Patients will only be eligible for this trial if they have disease with tumor measurable on the computed tomography (CT) scan or magnetic resonance imaging (MRI)
Patients must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 criteria.
Spinal compression or structurally unstable bone lesions suggesting impending pathologic fractures based on clinical findings and/or magnetic resonance imaging (MRI)
Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) / Magnetic Resonance Imagining (MRI) scans
Any lesion invading or having encasement ? 180 degrees around the wall of a major blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
All patients must have a CT or magnetic resonance imaging (MRI) of the brain within 90 days prior to registration; the brain CT or MRI should be performed with intravenous contrast (unless contraindicated)
Computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound of the abdomen and chest; required only if aspartate aminotransferase (AST)/alanine aminotransferase (ALT) or ALP is ?2 x ULN
>= 90% surgical resection of recurrent GBM confirmed by central radiology review by magnetic resonance imaging (MRI) with or without gadolinium per institutional guidelines; a computed tomography (CT) scan is allowable in place of MRI only in situations where an MRI is contraindicated (e.g., patient has a heart pacemaker, metallic devices in the eye, brain or spine, severe claustrophobia)
>1 focal lesions detected by functional imaging including PET/CT and/or whole body magnetic resonance imaging (MRI) AND have measurable disease by protein electrophoresis analyses as defined by the following:
Patients must have measurable disease in the pancreas; computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form
Radiological or clinical evidence (bone scan, computerized tomography [CT], and magnetic resonance Imaging [MRI]) of recurrence or progression within 30 days before randomization
All patients must have no evidence of persistent or metastatic disease as documented by a post-resection computed tomography (CT) of the chest/abdomen/pelvis or by CT chest + magnetic resonance imaging (MRI) abdomen/pelvis; the post-resection imaging studies should be performed within 4 weeks of registration on study
Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
Subjects with bone dominant disease with at least 2 skeletal metastases identified at baseline by bone scintigraphy and confirmed by CT/magnetic resonance imaging (MRI). Presence of metastases in soft tissue (skin, subcutaneous, muscle, fat, lymph nodes)and/or visceral metastases is allowed.
Patients must have measurable metastatic disease; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within 28 days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration; CT scans or MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Must have at least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or Magnetic Resonance Imaging [MRI])
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation
At least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan or magnetic resonance imaging [MRI])
Metastatic disease documented by greater than or equal to (>=) 1 bone lesions on 99mTc bone scan. Participants with a single bone lesion must have confirmation of bone metastasis by computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1.
A histologically proven, clinically significant lesion visible on mpMRI (magnetic resonance imaging) that is accessible to PRX302 transperineal injection.
Measurable disease defined per RECIST v. 1.1, or bone-only disease must have a lytic or mixed lytic blastic lesion that can be accurately assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Individuals with bone-only disease and blastic-only metastases are not eligible
Cohort A: Histologically confirmed metastatic non-small cell lung cancer (all histologic subtypes allowed) with radiographic evidence by magnetic resonance imaging (MRI) of at least one measurable brain lesion as defined by Response Assessment in Neuro-Oncology (RANO) criteria that does not require corticosteroids for symptomatic control
At least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters in its largest dimension by CT scan or magnetic resonance imaging)
Magnetic resonance imaging (MRI) or CT scans of brain if there are symptoms or signs suggesting brain metastases, must be done within 10 weeks prior to study entry
Subject has one or more tumors measurable by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; magnetic resonance imaging (MRI) is acceptable if a CT scan is contraindicated
Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
Documented recurrence by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI) performed within 28 days of entry in to the trial as per Response Assessment in Neuro-Oncology (RANO) criteria
Patients must have undergone an evaluation by magnetic resonance imaging (MRI) within 35 days of completing radiation and must also be within 7 days prior to registration; MRI must NOT demonstrate tumor progression, but patients with imaging changes consistent with pseudo-progression, stable neurologic function and not needing corticosteroid treatment are eligible
Histologically confirmed primary invasive adenocarcinoma of the breast with the size of the primary tumor being at least 1 cm on imaging by either mammography, ultrasound or breast magnetic resonance imaging (MRI)
Centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments
Pathologic (histologically or cytologically) documented extracranial diagnosis of primary lung cancer, melanoma, human epidermal growth factor receptor 2 (HER2)-amplified or immuno-positive breast cancer, or HER2-amplified or immuno-positive gastric cancer, with brain metastasis detected by contrast enhanced magnetic resonance imaging (MRI) or computed tomography (CT) is required; patients with concurrent leptomeningeal diseases are eligible
Has progression and measurable disease in the brain by magnetic resonance imaging (MRI) or computed tomography (CT)
Measurable disease at baseline as assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI)
Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan
Bi-dimensionally measurable disease on cross sectional imaging by X-ray Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Known leptomeningeal involvement by lymphoma or current metastatic brain disease; routine screening with central nervous system (CNS) imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated
Patients with stage IV malignancy (non-mesothelioma) must have had a brain scan (magnetic resonance imaging [MRI] or computed tomography [CT] with contrast) showing no evidence of disease progression within 8 weeks of study enrollment
Clinically negative lymph nodes as established by imaging (pelvic +/- abdominal computed tomography [CT] scan or magnetic resonance imaging [MRI]), nodal sampling, or dissection within 60 days prior to registration, except as noted immediately below:            \r\n* Patients with a single intermediate risk factor only do not require abdominopelvic imaging, but these studies may be obtained at the discretion of the treating physician; patients with 2 or 3 risk factors are required to undergo pelvic +/- abdominal CT or MRI\r\n* Patients with lymph nodes equivocal or questionable by imaging are eligible without biopsy if the nodes are =< 1.5 cm; any node larger than this on imaging will require negative biopsy for eligibility
At least 1 measurable (? 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
Documentation of mammogram, ultrasound and magnetic resonance imaging (MRI) of the ipsilateral breast all performed within 42 days prior to registration
To differentiate T3 lesions involving the mediastinal pleura from T4 lesions involving major vessels or organs, a chest magnetic resonance imaging (MRI) will be obtained; if any uncertainty remains, the patient will have four-dimensional computed tomography (CT) scans (4DCT) in an effort to determine the degree of tumor motion; a freely mobile tumor during ventilation will be judged to be T3 disease
Participants must be willing and able to undergo regular magnetic resonance imaging (MRI) scans of the brain
Complete clinical remission is defined as cancer antigen (CA)-125 within normal limits, examination and computed tomography (CT) or magnetic resonance imaging (MRI) without objective evidence of disease (non specific abnormalities are permitted on radiologic imaging)
Absence > 1 focal lesions on magnetic resonance imaging (MRI) studies
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
No centrally located tumors with radiographic evidence (CT or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) that is accessible to biopsy
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 25 weeks prior to registration at very high risk of recurrence as determined by 2 or more of the following combinations:\r\n* cT3a/b\r\n* PSA >= 20\r\n* Gleason score 8-10\r\n* >= 33% core involvement\r\n* OR any patient with pelvic lymph node involvement >= 1 cm as determined by pelvic computed tomography (CT) or magnetic resonance imaging (MRI) imaging will meet eligibility criteria for enrollment
Evidence of lymph node or bone metastasis by magnetic resonance imaging (MRI)/computed tomography (CT), bone scan, or biopsy (N1Mx or NxM1)
One or more of the following biomarkers of malignancy:\r\n* Clonal bone marrow plasma cell percentage >= 60%\r\n* Involved: uninvolved serum free light chain ratio >= 100\r\n* > 1 focal lesions on magnetic resonance imaging (MRI) studies
At least one recurrent or progressive brain metastasis(es) from any solid primary tumor that is visible on magnetic resonance imaging (MRI) as assessed by the patient’s treating physician
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment performed within 28 days of study inclusion
Patients with known or suspected brain metastases; however, if radiation therapy and/or surgery has been completed and serial evaluation by computed tomography (CT) (with contrast enhancement) or magnetic resonance imaging (MRI) over a minimum of 3 months demonstrates the disease to be stable and if the patient remains asymptomatic, then the patient may be enrolled; such patients must have no need for treatment with steroids or anti-epileptic medications
Baseline bone scan, chest x-ray and computed tomography (CT)/magnetic resonance imaging (MRI) of abdomen/pelvis demonstrating no metastatic disease
Patients with a histologically confirmed diagnosis of a primary CNS tumor that is recurrent, progressive or refractory to standard therapy; refractory disease will be defined as the presence of persistent abnormality on conventional magnetic resonance imaging (MRI) imaging that is further distinguished by histology (biopsy or sample of lesion) or advanced imaging, OR as determined by the treating physician and discussed with the primary investigator prior to enrollment; all tumors must have histological verification at either the time of diagnosis or recurrence except for patients with diffuse intrinsic brain stem tumors or optic pathway gliomas; patients with neurofibromatosis type-I (NF-1) associated CNS tumors are eligible if they meet all other eligibility criteria
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks prior to enrollment as documented by magnetic resonance imaging (MRI) or computed tomography (CT) imaging; treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 4 weeks prior to enrollment as documented by MRI or CT imaging
World Health Organization (WHO) grade IV glioma with definitive resection prior to consent, with residual radiographic contrast enhancing disease on the post-operative computed tomography (CT) or magnetic resonance imaging (MRI) of < 1 cm in maximal diameter in any axial plane
The ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) based volume estimation of the patient’s prostate gland should be =< 80 grams\r\n* For patients with prostate size > 60 grams cytoreduction therapy with ADT is recommended
The primary tumor must be resectable, defined as no involvement (abutment or encasement) of the major arteries (celiac, common hepatic, superior mesenteric) and interface between tumor and vessel (portal, superior mesenteric veins) wall to be less than 180 degrees of the circumference of the vessel wall; this should be confirmed by imaging of the abdomen, either by a contrast-enhanced computed tomography (CT) scan, or a contrast-enhanced magnetic resonance imaging (MRI) scan; PET scans will not be adequate alternatives; for each patient, the resectability must be reviewed by one of the study surgeons
Participants must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head computed tomography [CT]) 21 days prior to study registration; for patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration
Inability to undergo magnetic resonance imaging
Patients with newly diagnosed DIPG, who undergo a biopsy are eligible; patients with disseminated disease are not eligible, and magnetic resonance imaging (MRI) of the spine must be performed if disseminated disease is suspected by the treating physician
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain must be performed preoperatively and postoperatively (preferably within 96 hours of surgery), prior to the initiation of radiotherapy
Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician)
Patients must be able to undergo contrast enhanced magnetic resonance imaging (MRI) scans (or contrast enhanced computed tomography [CT] scans for patients unable to tolerate MRI)
Clinical stage II-IIIC (T2-4 N0-3 M0) by mammogram, ultrasound or magnetic resonance imaging (MRI)
Metastatic diseases measurable or evaluable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to RECIST 1.1 criteria; locally recurrent disease that is not amenable to potentially curative surgery or radiation therapy is also allowed; lesions must be >= 10 mm in size; recurrent or metastatic disease within a prior radiation field is acceptable as long as the disease has progressed in the radiation field by RECIST criteria
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) =< 28 days of study registration negative for disease recurrence
Evidence of metastatic disease by radiographic imaging (bone scan or other nodal or visceral lesions on computed tomography [CT] or magnetic resonance imaging [MRI])
Metastatic disease as evidenced by both lymphadenopathy and bony metastases or just bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen and pelvis within 28 days of registration; chest imaging is only required if clinically indicated or if there is known disease in the chest
Brain metastases per magnetic resonance imaging (MRI) or computed tomography (CT)\r\n* Note: patients who have had therapy for brain metastasis (i.e., surgical resection, whole brain radiation, or stereotactic radiosurgery [SRS] even if stable) are not eligible
Evidence of metastatic disease on previous bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI)
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Subject has measurable disease by radiographic techniques (computerized tomography [CT] or magnetic resonance imaging [MRI]);
Active and untreated central nervous system (CNS) metastasis (including metastasis identified during screening magnetic resonance imaging [MRI] or contrast computed tomography [CT])
Presence of existing lytic bone lesions either by skeletal X-ray, computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
There must be documented progression or recurrence of disease by magnetic resonance imaging (MRI) imaging or cerebrospinal fluid (CSF) studies since completion of last tumor-directed medical therapy; patients may have had surgical resection or radiation of tumor, and need not have measurable or evaluable disease at study entry
Phase Ib and II: surgical candidates, with moderate to high-risk pathologically-confirmed rectal cancer (stage cT3-4N0 or cT1-4N+); clinical staging by endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) is permitted
The patient must have post-operative contrast enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) unless only biopsy performed (in which case post-operative imaging is not routinely obtained; in these patients, the preoperative study will serve as baseline
All patients must have measurable residual disease defined as tumor measurable in two perpendicular diameters on magnetic resonance imaging (MRI); measurements are required for both the solid and cystic components
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT), magnetic resonance imaging (MRI); if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
Inability or unwillingness to have magnetic resonance imaging (MRI) scans performed (e.g. cardiac pacemaker-dependent)
Patient who is unable to undergo magnetic resonance imaging (MRI) brain and spine with gadolinium contrast.
Prostate volume (by ultrasound [US], computed tomography [CT] or magnetic resonance imaging [MRI] measurement) < 50 cc at time of enrollment
Evidence of metastatic disease as evidenced by a computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis and/or whole body bone scan (WBS); to be done prior to treatment start and up to 4 months prior to radical prostatectomy date
No increase in corticosteroid dose in the week prior to the baseline brain magnetic resonance imaging (MRI)
Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed < 30 days prior to registration) and complete neck exam from the skull base to the clavicles; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI); the primary tumor should be cT1 or T2 and cervical nodes cN1, N2a, or N2b based on clinical or radiographic criteria
Patients who underwent radiosurgery to treat a progressive lesion must have confirmation of tumor by tissue, magnetic resonance spectroscopy (MRS), magnetic resonance (MR) perfusion or positron emission tomography (PET) and the lesion must be measurable; NOTE: radiosurgery may be done to a lesion that will not be used for response evaluation and should be done > 2 weeks prior to enrollment
Unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) with and without contrast and with perfusion (or computed tomography [CT] if MRI is contraindicated); the scan must be performed within 14 days of starting treatment
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Metastatic disease documented by one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI), or
Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria
Local, locally-advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Patient must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol
No evidence of metastatic disease on imaging by whole body bone scan and computerized tomography (CT) or Magnetic Resonance Imaging (MRI) of the abdomen/pelvis within 6 weeks prior to randomization
Patients must have measurable disease, defined as at least one vestibular schwannoma (VS) > 0.4 ml (on volumetric analysis) that can be accurately measured by contrast-enhanced cranial magnetic resonance imaging (MRI) scan with fine cuts through the internal auditory canal (3 mm slices, no skip)
Imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) evidence of hemorrhage deemed significant by the treating physician (> grade 1); subjects with history of central nervous system (CNS) hemorrhage are not eligible
Radiographic evidence of spinal metastasis is required and may be obtained from radionuclide bone scans, computed tomography imaging, and magnetic resonance imaging; other studies may be used with principal investigator approval, but plain radiograph (X-ray) alone is not sufficient
Documented evidence of M1 disease by American Joint Committee on Cancer (AJCC) staging by bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI)
Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made\r\n* Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced MRI scan (or CT scan for patients with non-compatible devices) within 21 days prior to registration; Note: patients who did have surgery with a post-operative contrast-enhanced scan falling outside the 5-week window prior to registration, per definition of recent surgery, must have a repeat magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) within 21 days prior to registration\r\n* Patients must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:\r\n** New areas of tumor outside the original radiotherapy fields as determined by the investigator, or\r\n** Histologic confirmation of tumor through biopsy or resection, or\r\n** Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration\r\n* Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement
Metastatic disease on imaging (e.g., bone scan, computed tomography [CT], magnetic resonance imaging [MRI]); patients whose disease spread is limited to regional pelvic lymph nodes are not eligible; if lymph node metastasis is the only evidence of metastasis, it must be >= 2 cm in diameter
one site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm, Exception: For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.
Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan; for leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable
Patient with central nervous system (CNS) metastasis are required to have stable disease documented by being off treatment (surgery, radiation therapy) for at least 2 weeks, and four (4) weeks is preferred; a contrast enhanced brain computed tomography (CT) or brain magnetic resonance imaging (MRI) is required within 35 days of enrollment; patients with brain metastases who qualify for protocol therapy will be included in Cohort 2 (ineligible for treatment with bevacizumab)
Patients must have unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) performed no longer than 28 days prior to study registration
Subjects must have liver iron value of < 15 mg/g/dry weight; iron quantitation may be performed by imaging such as T2*magnetic resonance imaging (MRI) or by biopsy
Subjects must be free of known brain metastases by contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) scans or have successfully-treated brain metastases and be asymptomatic for more than 1 month
Appropriate stage for protocol entry, based upon the following minimum diagnostic workup:\r\n* History and physical examination, including a complete list of current medications\r\n* Chest x-ray (posteroanterior [PA] and lateral views)\r\n* Abdominal/pelvic computed tomography (CT) scan\r\n* Brain magnetic resonance imaging (MRI) if clinically indicated\r\n* Bone scan if clinically indicated
If patients have small-volume disease the current study will be restricted to patients with minimal ascites not causing abdominal distention/mesenteric thickening or not requiring paracentesis, or lesions =< 5 cm by spiral computed tomography (CT) or magnetic resonance imaging (MRI) at baseline
Preoperative evaluation to rule-out extra-uterine disease may include computed tomography (CT) scan, magnetic resonance imaging (MRI), or ultrasound; preoperative imaging is not mandatory for study enrollment
Patients with known contraindication to magnetic resonance imaging (MRI), such as cardiac pacemaker, shrapnel, or ocular foreign body; however, head computed tomography (CT) with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant’s CNS lesions are clearly measurable on the head CT
Able to undergo brain magnetic resonance imaging (MRI) with and without contrast
Patients must have a baseline evaluation including history and physical examination with neurological evaluation and magnetic resonance imaging (MRI) of the brain (with and without gadolinium-based contrast), all completed within 30 days prior to initiation of treatment
Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one untreated, or progressed liver metastasis that is >= 10 mm in longest diameter by spiral computed tomography (CT) scan or magnetic resonance imaging (MRI); the total volume of the tumors must be less than 50% of the liver volume
A brain scan should be performed within 14 days prior to registration and steroid dosing should be stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/computed tomography (CT) is required; the same type of scan, i.e., magnetic resonance imaging (MRI) or CT must be used throughout the period of protocol treatment for tumor measurement
Patients with greater than 9 discrete metastases on magnetic resonance imaging (MRI)
Primary disease > 7.5 cm in largest diameter as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan must be performed within 14 days prior to registration and on a steroid dose that has been stable or decreasing for at least 5 days; if the steroid dose is increased between the date of imaging and first dose of plerixafor, a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; a patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans
Treated (surgery, radiation therapy) but not clinically and radiographically stable 3 weeks after local therapy(as assessed by contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]), OR
At least one bi-dimensionally measurable lesion (greater than [>] 2 cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
Histologically confirmed HER2-positive (immunohistochemistry [IHC] 3+ or fluorescence in situ hybridization [FISH] amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (>= 5 mm on radiographic imaging); patients in whom brain metastases (BM) are asymptomatic and detected during routine brain magnetic resonance imaging (MRI) screening per institutional protocols are eligible
Maximum tumor dimension of =< 6 cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography [CT], magnetic resonance imaging [MRI] or PET/CT) and considered amenable for radiation therapy (RT)
Inability to have neither a magnetic resonance imaging (MRI) nor a computed tomography (CT) scan; patients with a pacemaker must undergo CT instead of MRI to be eligible
Prostate size as determined on magnetic resonance imaging (MRI) to be < 90 cc; prostate size can be determined on computed tomography (CT) scan if MRI is not available
At least 1 lesion (measurable by RECIST v1.1) that can be accurately assessed at baseline by computed tomography (CT)/magnetic resonance imaging (MRI) and is suitable for repeated assessment;
Diagnosis of HCC by biopsy-proven pathologic diagnosis or by clinical criteria as defined below: \r\n* Clinical criteria to be met if patient has a history of cirrhosis or chronic hepatitis B infection:\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by magnetic resonance imaging (MRI) or triple-phase computed tomography (CT) scan\r\n** Alpha-fetoprotein (AFP) of any value\r\n* Clinical criteria to be met if patient has no history of cirrhosis or chronic hepatitis B infection\r\n** Imaging abnormalities > 1 cm in size with classic enhancement by MRI or triple-phase CT scan\r\n** And AFP > 20 mg/dL
Subjects must have evidence of measurable disease per RECIST version 1.1 by radiographic techniques or magnetic resonance imaging
Patients with untreated central nervous system (CNS) metastases; patients should have a head CT/magnetic resonance imaging (MRI) within 28 days prior to treatment initiation; patients with previously excised/gamma knifed solitary or oligometastases and controlled disease are eligible
No evidence of metastatic disease on physical exam, computed tomography (CT)/magnetic resonance imaging (MRI)/chest x-ray (CXR), and bone scan within 4 weeks prior to randomization
Patients must be able to undergo an magnetic resonance imaging (MRI) scan
Patients must have MS using McDonald criteria supported by characteristic magnetic resonance imaging (MRI) changes
Patients must agree to undergo repeat clinical neurological examinations and brain magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of chemotherapy
Active central nervous system (CNS) involvement by malignancy (patients with known positive cerebrospinal fluid [CSF] cytology or parenchymal lesions visible by computed tomography [CT] or magnetic resonance imaging [MRI])
Patients must have at least 1 evaluable lesion. Lesions must be evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI)
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
At least 1 node ? 2 cm on computed tomography (CT) or magnetic resonance imaging (MRI) or
Patients must be able to undergo a pre-surgical magnetic resonance imaging (MRI) brain
Patients with non-quantifiable monoclonal proteins are eligible provided they meet other criteria for multiple myeloma and they have evaluable or measurable disease by other (radiographic, magnetic resonance imaging [MRI], computed tomography [CT], lytic measurable lesion on x-ray,) means
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
Presence of metastatic disease (M1) as assessed by computed tomography/ magnetic resonance imaging (CT/MRI) and/or whole-body radionuclide bone scan.
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Patients with metastatic disease, target lesion must be measurable using computed tomography (CT) or magnetic resonance imaging (MRI)
At least 1 measurable disease lesion >1.5 cm in at least one diameter by CT/CT-PET or magnetic resonance imaging (MRI) in an area of no prior radiation therapy, or in an area that was previously irradiated that has documented progression
Patients must have a patent portal vein as documented by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound
Patient should undergo brain imaging (CT scan or magnetic resonance imaging [MRI]) to rule out brain metastases
Imaging, a combination of at least two of the following (computed tomography [CT], magnetic resonance imaging [MRI], endoscopic ultrasound [EUS]) staging the pancreatic mass as “locally advanced”
Patients with clinically unstable central nervous system (CNS) metastasis (to be enrolled in the study, subjects must have confirmation of stable disease by magnetic resonance imaging [MRI] or computed tomography [CT] scan within 4 weeks of the first day of study defined treatment and have CNS metastases well controlled by steroids, anti-epileptics or other symptom-relieving medications)
Pain must be from one or two painful metastatic sites in the bone (additional less painful metastatic sites may be present)\r\n* Pain from the reported one or two metastatic sites must correlate with an identifiable tumor on CT, magnetic resonance imaging (MRI), or ultrasound (US) imaging\r\n* Metastatic tumors must be amenable to cryoablation with CT or MRI
Patients with >= 5 measurable brain metastases on a diagnostic-quality contrast-enhanced magnetic resonance imaging (MRI) obtained within 30 days prior to registration
No brain metastases detected by magnetic resonance imaging (MRI).
Patients must have measurable disease on magnetic resonance imaging (MRI) that has progressed after prior therapy; progressive disease (PD) will be defined as a >= 25% increase in the sum of the products of greatest perpendicular diameters of all measurable disease over the smallest sum observed (since treatment started) on gadolinium magnetic resonance imaging (Gd-MRI), the appearance of new lesions on scan, or clinical or neurologic worsening despite stable disease on the last 2 scans
Subjects must have at least two lesions:\r\n* At least one lesion must be safely amenable to irradiation and likely to meet criteria delineated in the judgement of the treating radiation oncologist; this can be a lesion that was previously irradiated as long as prior radiation was at least 6 months prior to projected first fraction of SBRT and as long as reirradiation dose constraints as outlined are being met\r\n* A separate, not-to-be-irradiated lesion measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Contraindication to magnetic resonance imaging
If patient has a history of brain metastases or leptomeningeal disease, lesions must be stable for at least 3 months (as documented by either head computed tomography [CT] or brain magnetic resonance imaging [MRI])
Patients must have measurable contrast-enhancing disease by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment; patient must be able to undergo MRI of the brain with gadolinium
Brain magnetic resonance imaging (MRI) documenting CR must be obtained within 30 days of study enrollment
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan.
Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate that is hormone refractory and with evidence of progressive metastatic disease following docetaxel treatment by any of the following:\r\n* Increased serum prostate-specific antigen (PSA) levels confirmed by 3 consecutive PSA measurements (at least 2 weeks apart)\r\n* Progression of bidimensionally measurable soft tissue (nodal) metastasis by computed tomography (CT) scan or magnetic resonance imaging (MRI) within the past 4 weeks and/or\r\n* Progression of bone disease by at least two new bone lesions on bone scan confirmed by a second bone scan
Patients with either skeletal pain or alkaline phosphatase that is > ULN must have a bone scan showing they do not have metastatic disease; suspicious findings on bone scan must be confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy
Measurable disease is defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (>/=) 1 centimeter (cm) on long access diameter on computed tomography (CT) or magnetic resonance imaging (MRI) scan or at least one bi-dimensionally measurable lymph node measuring >/=1.5 cm on short access diameter on CT or MRI scan
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments. Participants with radiographically stable, asymptomatic, previously irradiated lesions are eligible provided participant is >/=4 weeks beyond completion of cranial irradiation and >/=3 weeks off of corticosteroid therapy
Patient with known but adequately treated brain metastases and without central nervous system (CNS) disease progression as determined by computed tomography (CT) or magnetic resonance imaging (MRI) imaging within 4 weeks of the first dose of study drug
Patients with extraocular disease evident on magnetic resonance imaging (MRI) (extension into the optic nerve), massive choroidal/uveal invasion (grade IIC or IID per ARET0332) or disease outside the globe evident on MRI or physical examination would also be excluded
Subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI)
All patients must have their disease status documented by a complete physical examination and imaging studies within 4 weeks prior to the first dose of study drug. Imaging studies must include computerized tomography (CT) scan of neck, chest, abdomen, pelvis, and all known sites of resected disease in the setting of Stage IIIb/c or Stage IV disease, and brain magnetic resonance imaging ([MRI], brain CT allowable if MRI is contraindicated).
Patients must be free of active brain metastasis by contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI) scans within 4 weeks prior to enrollment; if known to have prior brain metastases, these must have been adequately managed with standard of care radiation therapy, stereotactic radiosurgery or surgery prior to registration on the study
Documented metastatic disease on bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI)
Appropriate diagnosis for protocol entry, based upon the following minimal diagnostic work-up:\r\n* History/physical examination within 8 weeks prior to registration and:\r\n* Suspicion of metastatic cancer to the vertebrae or multiple myeloma with a focus in a vertebral body(ies) and;  \r\n* The lesion must be identifiable with radiologic evidence (x-ray, bone scan, computed tomography [CT] scan, magnetic resonance imaging [MRI])
Medical contraindication to undergoing magnetic resonance (MR) imaging
Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality)
Histologically or cytologically confirmed squamous cell carcinoma, previously untreated stage II, III, or IVA HNC; patients with clinical stage III or IVA disease must undergo computed tomography (CT) or magnetic resonance imaging (MRI) to rule out the presence of distant metastases
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not available) of the brain must be performed within 14 days prior to study entry
Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography (CT) or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last cancer therapy within 6 months prior to randomization.
Known allergies against contrast agents required for magnetic resonance imaging (MRI) of intracranial lesions, or other contraindications for MRI, i.e., pacemaker
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Symptomatic leptomeningeal or brain metastases or spinal cord compression Note: Subjects previously treated for these conditions are eligible if they meet both of the criteria below: (1) have had stable CNS disease for at least 4 weeks after local therapy as assessed by imaging (contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]) prior to Day 1, and (2) are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 4 weeks prior to Day 1.
Brain lesion(s), if still present, must be confirmed stable (i.e., no increase in lesion size) for >= 6 weeks prior to randomization (stability must be confirmed with two consecutive magnetic resonance image (MRI) or computed tomography (CT) scans with contrast, AND
A cardiac T2* <10 ms by magnetic resonance imaging (MRI).
Patients must have magnetic resonance imaging (MRI) within 21 days of starting treatment
Patients must be able to undergo brain or spine magnetic resonance imaging (MRI) scans with intravenous gadolinium, based on tumor location(s) within 14 days prior to registration
Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Phlebotomy-dependent participants with splenomegaly by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging (? 450 cubic centimeters [cm^3]) or without splenomegaly (< 450 cm^3, unpalpable, or prior splenectomy)
Patient is able to be assessed by periodic dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) scan
Patients must have measurable progressive or recurrent disease by magnetic resonance imaging (MRI) within 2 weeks of starting treatment
Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan
Unable to undergo brain magnetic resonance imaging (MRI)
Patients must be free of brain metastasis by contrast-enhanced CT/magnetic resonance imaging (MRI) scans within 4 weeks prior to enrollment; if known to have prior brain metastases, must not have evidence of active brain disease after definitive therapy (surgery, radiation therapy, or stereotactic radiosurgery) on two successive MRI evaluations at least 3 months apart (one of which is =< 4 weeks prior to starting the study drugs)
Patients must have shown unequivocal evidence for tumor recurrence or progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast
Patients must have a magnetic resonance imaging (MRI) scan performed within 14 days prior to initial protocol treatment
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
Pre-operative computed tomography (CT)/magnetic resonance imaging (MRI) abdomen and pelvis within 90 days
No evidence of metastatic disease as documented by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans
Subject has no contraindication for computed tomography (CT) and/or magnetic resonance imaging (MRI) during screening and is able to complete a screening examination; CT and/or MRI within 6 months of screening is required
No evidence of cancer within 28 days prior to start of study treatment; this should be determined by imaging of the chest, abdomen and pelvis by computed tomography (CT) and/or magnetic resonance imaging (MRI); staging of the chest using chest x-ray in lieu of CT and/or MRI should not be used for this purpose
Clinical evidence for brain metastases (including carcinomatous meningitis) at baseline (may require imaging assessment, e.g. computed tomography [CT] or magnetic resonance imaging [MRI], for certain patient population), with the exception of those subjects who have previously-treated central nervous system (CNS) metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have had no requirement for steroids or enzyme- inducing anticonvulsants within 6 months prior to study entry
Patients must have a diagnostic quality magnetic resonance imaging (MRI) of the brain or if contraindicated then contrast computed tomography (CT) scan of the head performed within 28 days prior to registration
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) of the brain must be performed within 28 days prior to registration
Patients at institutions that elect to utilize central imaging review to confirm eligibility must be pre-registered prior to submission of these images; images should be submitted as soon as possible after the pre-registration magnetic resonance imaging (MRI) is obtained; turnaround time for this review will be =< 72 business hours after receipt of images by the Imaging and Radiation Oncology Core (IROC)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the brain with contrast within 30 days prior to registration
Visceral metastases (including cerebral metastases) from castration-resistant prostate cancer (CRPC) (> 2 lung and/or liver metastases [size >= 2 cm]; lymphadenopathy exceeding 6 cm in short-axis diameter or any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis), as assessed by computed tomography (CT), magnetic resonance imaging (MRI) or chest X-ray within the 8 weeks prior to registration
Patients must be receiving magnetic resonance imaging (MRI) scans at University of California San Francisco (UCSF)
Stable dose of corticosteroids for >= 5 days prior to baseline magnetic resonance imaging (MRI)
Subjects must have at least one lesion that is not within a previously radiated field that is evaluable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per RECIST version 1.1; if the subject’s only evaluable disease is within a previously radiated field, it must have demonstrated progression since the time of radiation
Has evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan or magnetic resonance imaging, based on RECIST version 1.1
Patients may have brain metastases if all lesions have been treated with stereotactic radiation therapy, craniotomy, or gamma knife therapy with no evidence of progression (demonstrated by identical imaging modality for 2 consecutive assessments/scans [magnetic resonance imaging (MRI) or CT scans], at least 4 weeks apart) and have not required steroids for at least 14 days prior to registration
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI). Exceptions include those participants who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids, and do not have neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).
At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks prior to the initiation of study treatment; stability must be confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) imaging and/or treating investigator determination
Confirmed primary brain tumor diagnosis via magnetic resonance imaging (MRI) and their neuro-oncologist
Magnetic resonance imaging (MRI)-incompatible head or neck tattoos
Additional exclusion criteria include participation in a scheduled resistance exercise program within 1 month of study entry; metal implants or other contraindications for the magnetic resonance imaging (MRI); history of diabetes, chronic renal disease characterized by a creatinine clearance of less than 30, uncontrolled hypertension; and a vitamin D status (25(OH)D) of > 32ng/mL
Centrally located tumors with radiographic evidence (computed tomography [CT] or magnetic resonance imaging [MRI]) of local invasion of major blood vessels
Patients unable to undergo magnetic resonance imaging (MRI) of the spine
No definitive evidence of brain metastases on brain computed tomography (CT) scan or brain magnetic resonance imaging (MRI) < 1 month prior to study entry
For the subset of participants who will undergo magnetic resonance imaging (MRI), ability to withstand lying down in small area (MRI scanner) for 50 minutes
Subjects must have measurable disease by computed tomography (CT) scans or magnetic resonance imaging (MRI) per RECIST 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to first dose of study drug
Subjects should have breast and axillary imaging with breast magnetic resonance imaging (MRI) (preferred) or breast and axillary ultrasound (US) within 4 weeks prior to treatment initiation
Active or untreated central nervous system (CNS) metastases as determined by Computed Tomography (CT) or magnetic resonance imaging (MRI) evaluation
Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head computed tomography [CT]) 21 days prior to study registration; for patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator)
Patients with known bone metastases, with evidence of corticol bone damage/lytric lesions/blastic lesions on standard imaging studies (computed tomography [CT]/magnetic resonance [MR])
Acute ischemic stroke within the prior four weeks, defined as a new neurologic deficit(s) with magnetic resonance imaging (MRI) evidence of acute ischemia in a referable location, and no clinical or radiologic indication of a non-cerebrovascular mimic, such as a brain metastasis, as the etiology of the deficit(s)
Radiographic (X-ray, or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
Immediate need for magnetic resonance imaging (MRI)
Patients must have a magnetic resonance imaging (MRI) or CT brain within 4 weeks prior to study entry to rule out asymptomatic brain metastases
Participant had a breast magnetic resonance imaging (MRI) that was performed after the diagnosis of ADH but before surgical excision.
Screening contrast-enhanced magnetic resonance imaging (MRI) or 99mTc-sestamibi based imaging of the breast(s) within the prior 12 months or planned within the next two years
Patients who are thought to have a breast magnetic resonance imaging (MRI) within 1 year prior to the study
Arm 2 patients must have lymph node, soft tissue, or visceral metastatic disease measuring >= 1 cm, or bone metastases, documented by prior CT or magnetic resonance imaging (MRI) imaging; Arm 2 patients may have hormone-sensitive or castrate-resistant disease and may be receiving treatment with hormonal or other therapies
Previous CT scan, magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP) or EUS of the abdomen in the past three years
Patient must not have previously had molecular breast imaging (MBI, multiplexed ion beam imaging [MIBI])
Patients must have achieved a documented complete response to treatment based on normal cancer antigen (CA)-125 (per the institution’s upper limit of normal) and computed tomography (CT) scan or magnetic resonance imaging (MRI) with contrast (i.e. there must be no clinical evidence of persistent or recurrent disease based on CA-125 and CT scan or MRI with contrast)
Alpha feto protein (AFP) levels within normal institutional limits or judged to be not clinically significant by the investigator; Exception: If deemed clinically significant, then liver imaging must be available within previous 6 months (e.g., ultrasound, computed tomography [CT] scan, magnetic resonance imaging [MRI]) showing no evidence of hepatocellular carcinoma
Advanced chronic pancreatitis as determined by the following criteria: EUS score greater than 6, calcifications in combination with atrophy and/or dilation of >= 5 mm, or evidence of advanced chronic pancreatitis by computed tomography (CT) or magnetic resonance imaging (MRI) results in the past 12 months
Confirmed diagnosis of liver cirrhosis assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging [MRI]), or liver biopsy
Subjects must have had a negative bone scan, and computed tomography (CT) of abdomen and pelvis within 16 weeks prior to registration; additional forms of imaging (Prostascint scan, magnetic resonance imaging [MRI]) may be substituted for a CT scan of the abdomen and pelvis if clinically indicated
Confirmed diagnosis of liver cirrhosis (Child-Pugh A or B) assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging (MRI), or liver biopsy
Patients must have an unaffected, non-irradiated contralateral breast with a baseline breast density score of > 25% as measured by standard digital mammography (BIRADs score > 2) or magnetic resonance imaging (MRI) performed within 12 months of randomization to the study
Claustrophobia and/or inability to lie flat in magnetic resonance imaging (MRI) machine
Patients with breast implants are usually permitted to have an magnetic resonance imaging (MRI); check with the MRI technician to confirm
Subjects with bone dominant disease with at least 2 skeletal metastases identified at baseline by bone scintigraphy and confirmed by computed tomography (CT)/magnetic resonance imaging (MRI).
Patients must have measurable, supratentorial contrast-enhancing progressive or recurrent glioblastoma or gliosarcoma by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment; patient must be able to tolerate MRIs
Histologically proven diagnosis of solid tumor malignancy and Magnetic Resonance (MR) imaging documenting brain lesions.
Known active metastases to the brain, spinal cord or leptomeninges unless adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks of first study treatment as documented by magnetic resonance imaging (MRI) or computed tomography (CT) imaging and having no ongoing requirement for steroids
Measurable disease per RECIST 1.1 or bone-only disease with lytic component. Patients with bone-only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by computerized tomography (CT) or magnetic resonance imaging (MRI). Patients with bone-only disease without a lytic component (ie, blastic-only metastasis) are not eligible.
More than 1 focal lesion >=5 millimeter (mm) in diameter by magnetic resonance imaging (MRI)
Patients must have a biopsy marker placed within the tumor bed with imaging confirmation (preferably mammogram but ultrasound or magnetic resonance imaging [MRI] is acceptable) of marker placement prior to neoadjuvant chemotherapy
Patients with untreated focal liver observations on liver ultrasound or multiphase contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) performed as part of clinical standard of care within 4 weeks before patient enrollment
Clinical stage I grade 1-2 endometrial cancer also eligible with deep myoinvasion >= 50% shown on preoperative (preop) magnetic resonance imaging (MRI) and/or elevated preop cancer antigen (CA)-125 > 35 U/ml
Patients with no contra-indications to magnetic resonance (MR) imaging
Diagnostic CT or magnetic resonance imaging (MRI) scan within 2 months of study entry
No contra-indications to magnetic resonance imaging (MRI), including permanent pacemaker, implantable device, aneurysm clip, or severe claustrophobia (for patients planning to be imaged on PET/magnetic resonance [MR] scanner)
(Part 3, suspected recurrent GBM patients ONLY): Any patient with histopathologically proven GBM who, on a standard of care surveillance brain magnetic resonance imaging (MRI), has an imaging change suspicious for GBM recurrence, and whose treatment plan for the recurrence does not include surgery
Patient agrees to undergo, prior to the procedure, magnetic resonance imaging (MRI, within 14 days and preferably with 3 days of the planned procedure) with perfusion, diffusion and spectroscopic imaging.
Diagnostic CT or magnetic resonance imaging (MRI) as part of the PET study or performed within one month of PSMA PET
Be able to undergo magnetic resonance (MR) imaging
Any contraindication to the use of contrast and/or general guidelines for magnetic resonance (MR) imaging as per standard Department of Radiology imaging guidelines
Had a prior 68Ga DOTATATE PET/CT scan and a CT or magnetic resonance imaging (MRI) with or without contrast performed within 3 months before signing the consent, without interval treatment other than a somatostatin analog
Contraindication for magnetic resonance imaging
Patient must have a solid tumor with a short-axis greater than or equal to 1 cm (by CT, magnetic resonance imaging (MRI), ultrasonography or mammography) to allow reliable PET imaging.
Patients must be able to tolerate magnetic resonance (MR) imaging required by protocol
Diagnostic CT or magnetic resonance imaging (MRI) performed within 30 days prior to the 68Ga-RM2 PET
Contraindication to magnetic resonance imaging (MRI).
At least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) that is seen on CT, magnetic resonance imaging (MRI), or FDG PET/CT
Biopsy proven or clinically documented metastatic breast cancer with at least one lesion outside the liver by standard imaging (e.g. CT, magnetic resonance imaging [MRI], bone scan, ultrasound, fludeoxyglucose F 18 [FDG] PET/CT)
Contraindication to magnetic resonance (MRI) imaging, as determined through review of the University of California, San Francisco (UCSF) MRI screening form by study investigator
Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS) biopsy, followed by histology
At least 2 metastatic soft tissue or osseous lesions identified on conventional imaging (CT, magnetic resonance imaging [MRI] or bone scan)
Presence of at least one target liver or other intra-abdominal lesion detected by standard staging scans that, in the judgment of study investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging:\r\n* Target lesion must measure >= 1.0 cm in long axis diameter on computed tomography (CT) or magnetic resonance imaging (MRI)
Standard gadolinium-enhanced magnetic resonance imaging (MRI) changes that are considered indeterminate for tumor progression versus (vs.) treatment-related changes by the neuroradiologist or clinician within 24 weeks of completion of radiation
Completed radiographic evaluation with whole-body bone scan (99mTc-MDP or Na18F) and cross-sectional imaging (CT or magnetic resonance imaging [MRI]) of the abdomen and pelvis =< 42 days prior to study enrollment
Documented visceral metastases or current lymphadenopathy > 3 cm by standard imaging (e.g. magnetic resonance imaging [MRI], CT, ultrasound, fludeoxyglucose [FDG] PET/CT)
Patients with non-magnetic resonance imaging (MRI) compatible implanted metallic foreign bodies are excluded from this study
Have at least one kidney lesion identified but incompletely characterized on a non-contrasted ultrasound (US), computed tomography (CT), or magnetic resonance (MR) exam for which the patient’s provider recommends follow-up studies or further evaluation with an additional imaging tests.
PATIENT: Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT] or ultrasound [US]) in the 24 hours prior to the research US exam
For patients with organ confined renal tumors to be enrolled, the renal mass must be >= 1 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage T1a-T4 (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney
Patient must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by radiological evaluation (ultrasound, mammography, magnetic resonance imaging [MRI], computed tomography [CT], PET) or physical examination\r\n* Patients with evaluable osseous metastasis that are lytic or mixed lytic-sclerotic are eligible\r\n* Patients with hepatic lesions may be eligible provided the location of the lesion is peripheral or not too close to hepatic duct; decision on hepatic lesion eligibility will be made by the principal investigator or sub-investigator after careful review of all available imaging to ensure evaluation of the lesion will not be obscured by normal hepatobiliary excretion of 18F-FFNP
Patients whose lung tumors are being monitored by magnetic resonance (MR) imaging as part of standard clinical care
Recurrent or metastatic cancer that is of known or suspected breast origin - may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, magnetic resonance imaging [MRI], FDG PET/CT)
Diagnosis of HCC with one or more of the following:\r\n* Liver mass (>= 1 cm) with arterial phase contrast enhancement and early washout on subsequent phases by CT or magnetic resonance imaging (MRI)\r\n* Suggestive imaging findings plus alpha-feto protein (AFP) > 200 mg/dL; or\r\n* Tumor confirmed by arteriography
Allergy or relative contraindications to magnetic resonance imaging (MRI) contrast agents
Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week
GROUPS 1, 2, AND 3: Group 2 participants identified as having IPMN on standard radiographic imaging that meets criteria for resection based on symptoms or on conventional imaging (computed tomography [CT] or MRI) findings
Measurable or evaluable disease, lesions that have not been previously radiated, with clinically indicated imaging evaluation performed within 4 weeks prior to study entry (computed tomography [CT], magnetic resonance imaging [MRI], fluorodeoxyglucose [FDG]-PET or bone scan); patients requiring concurrent radiation treatment are not eligible unless additional lesions that are not being irradiated and are assessable for targeting are present
No contraindications to magnetic resonance imaging (MRI)
Suspected first recurrence of a glioblastoma tumor by clinical measures and/or magnetic resonance imaging (MRI)
A CXR (chest x-ray), liver enzymes, and a head and neck computed tomography (CT) or magnetic resonance imaging (MRI) and an ultrasound negative for clinical evidence of metastasis
Subjects must have had radiographically evaluable or measurable disease with standard magnetic resonance (MR) imaging
Visible lesions by either CT, bone imaging, or MRI consistent with disease
Adult patients who require monitored anesthesia for magnetic resonance imaging (MRI) scanning
Magnetic resonance imaging (MRI) or transrectal doppler ultrasound demonstrating at least one target lesion
Presence of a genetic disorder other than NF1 that effects cognition or is associated with magnetic resonance (MR) imaging abnormalities (e.g. tuberous sclerosis)
Completed staging evaluation with bone scan as well as CT or magnetic resonance imaging (MRI) of the abdomen and pelvis at least 45 days prior to study enrollment
CT/magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry
Patients with reoccurrence of brain tumor\r\n* The principal investigator or co-principal investigator (PI) must review magnetic resonance imaging (MRI) and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial 09-177) OR
Known or suspected somatostatin receptor positive neuroendocrine tumors (NETs) (e.g. carcinoid, pancreatic neuroendocrine tumors, and pheochromocytoma); supporting evidence may include magnetic resonance imaging (MRI), CT, biochemical markers, and or pathology report
Patient must have newly diagnosed brain metastases visible on brain magnetic resonance imaging (MRI); a biopsy of the lesion is not required as long as the patient has a biopsy-proven malignancy elsewhere and a clinician deems the lesion to be metastatic
Diagnostic imaging of the abdomen utilizing either CT with contrast, magnetic resonance imaging (MRI), or PET/CT no greater than 6 weeks prior to registration
Primary or recurrent/metastatic lesion size >= 1.5 cm as determined by imaging studies (ultrasonography, mammography, computed tomography [CT] or magnetic resonance imaging [MRI]) or physical examination
Inability to undergo a magnetic resonance imaging (MRI) or PET scan (e.g., claustrophobia or metal implant)
Participants must be willing and able to undergo regular magnetic resonance imaging (MRI) scans of the brain
Patients with at least 1 measurable tumor lesion as assessed by Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) according to RECIST 1.1.
Patients must have measurable disease, documented by clinical, radiographic or histologic criteria; disease must be bi-dimensionally measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients who received anti-tumor therapy after histopathologic transformation to glioblastoma must have shown unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan if MRI is contraindicated)
Visible lesions by either computed tomography (CT), bone scan or magnetic resonance imaging (MRI) consistent with metastatic disease\r\n* Metastatic progressive disease\r\n* Imaging modalities:\r\n** Bone scan: new osseous lesion and/or\r\n** MRI or CT: an increase in measurable soft tissue disease or the appearance of new sites of disease OR\r\n* Prostate specific antigen (PSA) changes showing androgen independent, minimum number of determinations: 3; interval >= 1 week; percentage increase over range of values: 25%\r\n* PSA changes showing androgen independent, minimum number of determinations: 2; interval >= 2 week; percentage increase over range of values: 25%
Known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; medulloblastoma; pheochromocytoma; supporting evidence may include magnetic resonance imaging (MRI), CT, biochemical markers, and/or pathology report
Able to tolerate magnetic resonance (MR) imaging required by protocol, to be performed at an American College of Radiology Imaging Network (ACRIN)-qualified facility and scanner
Patients who have received any contrast medium (X-ray, magnetic resonance imaging [MRI], computed tomography [CT], of US) in the 24 hours prior to the research US exam
The subject has concordant magnetic resonance imaging (MRI)/1H MRSI findings from a magnetic resonance (MR) staging exam at UCSF performed prior to the 13C MRSI exam performed in this study with investigational medicinal product (IMP), or is willing to undergo MRI/1H MRSI in connection with the study exam
Diagnostic quality abdominal imaging (CT or magnetic resonance imaging [MRI]) within the past 45 days
Unable to receive or tolerate magnetic resonance imaging (MRI) scan after evaluation of MRI screening form
Be scheduled for contrast-enhanced magnetic resonance imaging (MRI)/computed tomography (CT) to monitoring of RCC recurrence as part of their 8, 12, 18, 24, or 36 month CT/MRI follow up
Able to undergo experimental imaging studies, as well as conventional bone and body imaging
imaging modalities (bone scan, MRI or CT) OR
Inability to undergo magnetic resonance imaging (i.e. those patients with automated implantable cardioverter defibrillators [AICD]/pacemakers)
Presence of at least one measurable or detectable metastasis as defined by bone scintigraphy, computed tomography (CT) scan appearance (magnetic resonance imaging [MRI] if indicated), or plain x-ray appearance
Patients must have radiographic evidence of upper tract urothelial cancer by computed tomography (CT), magnetic resonance imaging (MRI) or intravenous pyelogram (IVP) in order to undergo this procedure
The lesion shows intratumoral arterial phase enhancement on contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
For iNHL: measurable nodal disease, defined as the presence of >= 1 nodal lesion that measures >= 2 cm in a single dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
BIODISTRIBUTION COHORT: At least one lesion >= 1.0 cm that is seen on standard imaging (e.g. CT, magnetic resonance imaging [MRI], ultrasound, fludeoxyglucose F-18 [FDG] PET/CT)
Participants requiring conscious sedation for magnetic resonance (MR) imaging
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
Patients with clinically localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy (RP) with curative intent and have any the following clinico-pathologic features: (1) Gleason score sum >= 4+3 or any Gleason 5, (2) PSA > 20, and/or (3) clinical stage >= T3a (staging by magnetic resonance imaging [MRI] is allowed)
At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment
Computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis within 28 days of Cycle 1 Day 1.
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
Expected to undergo magnetic resonance imaging (MRI) within two weeks following the study procedure
Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
DCIS must be >= 1 cm based on extent of calcifications, presence of a mass on ultrasound OR enhancement on magnetic resonance imaging (MRI) OR
